Straits Times Index
3,388.52 +7.68 (+0.23%) S&P 500
4,164.00 +52.92 (+1.29%) Dow
34,156.69 +265.67 (+0.78%) Nasdaq
12,113.79 +226.34 (+1.90%) BTC-USD
23,172.45 +177.52 (+0.77%) CMC Crypto 200
534.84 +8.89 (+1.69%)
Sesen Bio, Inc. (SESN)
After hours:
- Business Wire
Sesen Bio Files Investor Presentation in Connection with Pending Carisma Therapeutics Merger
CAMBRIDGE, Mass., February 02, 2023--Sesen Bio, Inc. (NASDAQ: SESN) today filed an investor presentation highlighting its value maximizing merger with Carisma Therapeutics Inc. ("Carisma"). The presentation can be found at www.SesenBioandCarisma.com.
- Business Wire
Sesen Bio Receives NASDAQ Delisting Notice
CAMBRIDGE, Mass., January 30, 2023--Sesen Bio, Inc. (Nasdaq: SESN) ("Sesen Bio" or the "Company") today announced that it has received notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") that, based upon the Company’s non-compliance with the $1.00 bid price requirement for continued listing on The Nasdaq Capital Market, the Company’s common stock is subject to delisting.
- Business Wire
Sesen Bio Reiterates Confidence that Pending Merger with Carisma is in Best Interests of Stockholders
CAMBRIDGE, Mass., January 26, 2023--Sesen Bio, Inc. (Nasdaq: SESN) today issued the following statement reiterating the Company’s confidence in, and commitment to, the pending merger with Carisma Therapeutics Inc. (Carisma) in response to the release issued yesterday by Bradley Radoff and Michael Torok and their affiliates (collectively, the "Investor Group"):
